DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Poveda A, Floquet A, Ledermann JA. et al.
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
J Clin Oncol 2020;
38(15_suppl): 6002
doi:10.1200/JCO.2020.38.15_suppl.6002
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.